应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BCAX Bicara Therapeutics
盘后交易 11-22 18:15:37 EST
18.09
+0.32
+1.80%
盘后
18.09
+0.00
0.00%
16:37 EST
最高
18.72
最低
17.51
成交量
54.29万
今开
17.51
昨收
17.77
日振幅
6.81%
总市值
9.84亿
流通市值
5.15亿
总股本
5,442万
成交额
998.59万
换手率
1.91%
流通股本
2,845万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Bicara Therapeutics Inc.2024财年第三财季实现净利润-17.48百万美元,同比增加23.50%
市场透视 · 11-19
Bicara Therapeutics Inc.2024财年第三财季实现净利润-17.48百万美元,同比增加23.50%
美国研究综述-AMN 医疗保健服务公司、Chart Industries 公司、家得宝公司
Reuters · 11-13
美国研究综述-AMN 医疗保健服务公司、Chart Industries 公司、家得宝公司
更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元
路透中文 · 10-24
更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元
更新版 2-随着医疗保健行业上市热潮的兴起,上游生物和另外两家美国生物技术初创公司纷纷定价 IPO
路透中文 · 10-11
更新版 2-随着医疗保健行业上市热潮的兴起,上游生物和另外两家美国生物技术初创公司纷纷定价 IPO
更新版 2-TPG 支持的 CeriBell 在美国首次公开募股中寻求高达 5.78 亿美元的估值
路透中文 · 10-09
更新版 2-TPG 支持的 CeriBell 在美国首次公开募股中寻求高达 5.78 亿美元的估值
BUZZ-TPG 支持的 Bicara Therapeutics 在纳斯达克市场首次亮相即大涨
Reuters · 09-14
BUZZ-TPG 支持的 Bicara Therapeutics 在纳斯达克市场首次亮相即大涨
更新版 1-由 TPG 支持的 Bicara Therapeutics 首次上市即股价大涨 46
Reuters · 09-14
更新版 1-由 TPG 支持的 Bicara Therapeutics 首次上市即股价大涨 46
异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%
异动解读 · 09-14
异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%
由 TPG 支持的 Bicara Therapeutics 首次上市即大涨 45.8%
Reuters · 09-14
由 TPG 支持的 Bicara Therapeutics 首次上市即大涨 45.8%
更新 2-Zenas 生物制药公司首次上市股价上涨近 8
Reuters · 09-14
更新 2-Zenas 生物制药公司首次上市股价上涨近 8
TPG 支持的 Bicara Therapeutics 在美国首次公开募股中融资 3.15 亿美元
Reuters · 09-13
TPG 支持的 Bicara Therapeutics 在美国首次公开募股中融资 3.15 亿美元
加载更多
公司概况
公司名称:
Bicara Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Bicara Therapeutics Inc.于2018年12月12日在特拉华州注册成立。他们是一家临床阶段的生物制药公司,致力于为实体瘤患者带来变革性的双功能疗法。他们的主要项目阿法是一种双功能抗体,它结合了两个临床验证的靶点,即表皮生长因子受体(EGFR)导向的单克隆抗体和结合人类转化生长因子β(TGF-b)的结构域。通过这种双靶向机制,阿法有可能通过同时阻断癌症细胞固有的EGFR存活和增殖,以及肿瘤微环境(TME)中的免疫抑制性TGF-b信号传导,发挥强大的抗肿瘤活性。Ficerafusp alfa通过与肿瘤细胞上的EGFR结合,将TGF-b抑制剂直接引入TME,他们认为这将导致持久的反应和总生存率或OS的增加,同时减少通常与全身TGF-b抑制相关的不良反应。
发行价格:
--
{"stockData":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":18.09,"timestamp":1732309200000,"preClose":17.77,"halted":0,"volume":542930,"hourTrading":{"tag":"盘后","latestPrice":18.09,"preClose":18.09,"latestTime":"16:37 EST","volume":129708,"amount":2346417.72,"timestamp":1732311449966},"delay":0,"floatShares":28450341,"shares":54415619,"eps":-18.087975,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.32,"latestTime":"11-22 18:15:37 EST","open":17.51,"high":18.72,"low":17.51,"amount":9985931.23724,"amplitude":0.068092,"askPrice":27.68,"askSize":100,"bidPrice":17,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-18.087975,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1732323600000},"adr":0,"listingDate":1726200000000,"adjPreClose":17.77,"preHourTrading":{"tag":"盘前","latestPrice":17.7,"preClose":17.77,"latestTime":"09:28 EST","volume":3,"amount":51.599999999999994,"timestamp":1732285680104},"postHourTrading":{"tag":"盘后","latestPrice":18.09,"preClose":18.09,"latestTime":"16:37 EST","volume":129708,"amount":2346417.72,"timestamp":1732311449966},"volumeRatio":1.208839,"impliedVol":0.8534,"impliedVolPercentile":0.6842},"requestUrl":"/m/hq/s/BCAX","defaultTab":"news","newsList":[{"id":"2484130309","title":"Bicara Therapeutics Inc.2024财年第三财季实现净利润-17.48百万美元,同比增加23.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484130309","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484130309?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010416,"startTime":"0","endTime":"0","summary":"11月19日,Bicara Therapeutics Inc.公布财报,公告显示公司2024财年第三财季净利润为-17.48百万美元,同比增加23.50%;其中营业收入为0.00美元,每股基本收益为-0.32美元。机构评级:截至2024年11月19日,当前有4家机构对Bicara Therapeutics Inc.目标价做出预测,其中目标均价为42.05美元,其中最低目标价为36.00美元,最高目标价为48.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180024abcede94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180024abcede94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BCAX"],"gpt_icon":0},{"id":"2483082300","title":"美国研究综述-AMN 医疗保健服务公司、Chart Industries 公司、家得宝公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2483082300","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483082300?lang=zh_cn&edition=full","pubTime":"2024-11-13 19:30","pubTimestamp":1731497406,"startTime":"0","endTime":"0","summary":" 路透11月13日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价,其中包括 AMN 医疗保健服务公司、Chart Industries 公司和家得宝公司。* 908 Devices Inc :Leerink Partners将目标价从12美元下调至4美元 * 908 Devices Inc :Leerink Partners 将其目标价从 \"跑赢大盘 \"下调至 \"跑输大盘\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2249611893.SGD","DOCS","COLD","BBIO","FDX","GTLS","APA","EWTX","AMN","BCAX","BMY","LU0128525689.USD","IRON","HCSG","CSX","ARCH","CAVA","COTY","AISP","BLFS","HD","SATS","BHVN","CRNX","BK4505","DCOM","ALB","BK4566","DAY","AESI","DOX","BLTE","LU2133065610.SGD","CHH","CHGG","LU0256863902.USD","CHRW","LU2106854487.HKD","MASS","ABBV","BK4567","ALIT","COGT","LU2065731478.USD","BK4534","ATLC","CCCS","ACLX","AXSM","CLF"],"gpt_icon":0},{"id":"2477636551","title":"更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2477636551","media":"路透中文","labels":["Shareholding Changes","Product Release","event"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477636551?lang=zh_cn&edition=full","pubTime":"2024-10-24 20:08","pubTimestamp":1729771713,"startTime":"0","endTime":"0","summary":"更新版 2-高盛支持的药物开发商 Septerna 在美国首次公开募股中目标估值 7.43 亿美元第 3-5 段补充了生物技术行业的背景,第 6-7 段补充了 Septerna 的主要药物。路透10月24日 - 高盛支持的药物开发商赛普特纳公司周四表示,该公司将在美国进行规模更大的首次公开募股,寻求获得 7.431 亿美元的估值,这表明投资者对这一资本密集型行业的乐观情绪。高盛持有 Septerna 5.4% 的股份,该公司目前的目标是通过出售近 1530 万股每股 18 美元的股票筹集 2.75 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241024:nL4S3M01LN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes,Product Release,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","LU0106831901.USD","IE0002270589.USD","IE0004086264.USD","BK4588","LU2237438978.USD","BK4552","IE00B19Z3581.USD","BK4139","IE0004091025.USD","LU2237443622.USD","LU2237443465.HKD","BCAX","IE00B19Z3B42.SGD","LU2237443978.SGD","MBX","BK4007","LU2237443895.HKD","IE00BSNM7G36.USD","UPB","BK4127","LU2237443382.USD","IE00BFXG1179.USD","BK4585","BK4504","BK4533","LU1791807156.HKD","BIOA","LU1668664300.SGD","LU2237443549.SGD","BK4550"],"gpt_icon":0},{"id":"2474031923","title":"更新版 2-随着医疗保健行业上市热潮的兴起,上游生物和另外两家美国生物技术初创公司纷纷定价 IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2474031923","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474031923?lang=zh_cn&edition=full","pubTime":"2024-10-11 08:01","pubTimestamp":1728604880,"startTime":"0","endTime":"0","summary":"更新版 2-随着医疗保健行业上市热潮的兴起,上游生物和另外两家美国生物技术初创公司纷纷定价 IPO全文改写;第 3-10 段增加了细节和背景介绍。路透10月11日 - 周四,三家美国医疗保健初创企业首次公开募股定价,其中包括Upstream Bio UPB.O,该公司以约8.3亿美元的估值募集了2.55亿美元。Dealogic 的数据显示,9 月份是今年医疗保健行业 IPO 最繁忙的月份。CAMP4 的首次公开募股定价为每股 11 美元,远低于其 14 至 16 美元的目标区间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241011:nL4T3LN006:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BIOA","TPG","IPO","BK4135","BK4139"],"gpt_icon":0},{"id":"2474225168","title":"更新版 2-TPG 支持的 CeriBell 在美国首次公开募股中寻求高达 5.78 亿美元的估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2474225168","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474225168?lang=zh_cn&edition=full","pubTime":"2024-10-09 19:56","pubTimestamp":1728475011,"startTime":"0","endTime":"0","summary":"更新版 2-TPG 支持的 CeriBell 在美国首次公开募股中寻求高达 5.78 亿美元的估值CeriBell 发行 1,060 万股股票,此前为 670 万股首次公开募股价格区间从每股 14-16 美元提高到 16-17 美元部分现有投资者可购买价值高达 4000 万美元的股票在第 6、7 和 9-12 段增加了有关公司和首次公开募股的背景和详细信息。路透10月9日 - 由 TPG 支持的医疗设备制造商 CeriBell 周三表示,该公司将在美国进行规模更大的首次公开募股,目标估值高达 5.783 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241009:nL4T3LL12P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","BK4585","LU1791807156.HKD","LU0070302665.USD","LU0648000940.SGD","LU1074936037.SGD","LU1668664300.SGD","LU1201861165.SGD","IE00BLSP4452.SGD","LU0256863811.USD","BK4553","LU0130103400.USD","LU0234572021.USD","LU0306806265.USD","BK4559","LU0971096721.USD","IE00BLSP4239.USD","LU0321505868.SGD","BK4207","LU1718418525.SGD","LU0417517546.SGD","LU0053666078.USD","BCAX","BK4504","LU0310800965.SGD","IE00BZ1G4Q59.USD","LU0640476718.USD","LU1280957306.USD","LU0868494617.USD","BK4588","LU0321505439.SGD","BK4135","IE00B7SZLL34.SGD","LU1496350502.SGD","TPG","BAC","LU2129689514.USD","BIOA","BK4139","LU0128525689.USD","LU1162221912.USD","LU1894683264.USD","LU1894683348.USD","IE00B19Z3581.USD","LU1201861249.SGD","LU1267930227.SGD","LU0980610538.SGD","IE00BKVL7J92.USD","LU1496350171.SGD","BK4534"],"gpt_icon":0},{"id":"2467702802","title":"BUZZ-TPG 支持的 Bicara Therapeutics 在纳斯达克市场首次亮相即大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2467702802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467702802?lang=zh_cn&edition=full","pubTime":"2024-09-14 02:20","pubTimestamp":1726251654,"startTime":"0","endTime":"0","summary":" 9月13日 - ** 癌症疗法开发商 Bicara Therapeutics 在纳斯达克首次上市时股价大涨 50%,最后上涨 39%,报收于 25.02 美元。* * 由另类资产管理公司 TPG 支持的 Bicara,通过出售 1750 万股股票筹集了 3.15 亿美元,其定价为市场范围的上限。我们可以从今天上市的另外两家公司 中看到明显的迹象,这两家公司都提高了发行规模--IPOX 研究分析师 Lukas Muehlbauer 说。** 摩根士丹利、TD Cowen、Stifel 和 Cantor Fitzgerald 为承销商。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQQ","TPG","NQmain","PSQ","QLD","BK4135","MNQmain","SQQQ","BK4139","QID","BCAX",".IXIC","ARTL","BK4007","LENZ"],"gpt_icon":1},{"id":"2467093437","title":"更新版 1-由 TPG 支持的 Bicara Therapeutics 首次上市即股价大涨 46","url":"https://stock-news.laohu8.com/highlight/detail?id=2467093437","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467093437?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:22","pubTimestamp":1726248149,"startTime":"0","endTime":"0","summary":" 路透9月13日 - 周五,Bicara Therapeutics 首次上市时股价大涨近46%,表明投资者对这家由TPG支持的癌症疗法开发商兴趣浓厚。公司股票开盘价为每股26.25美元,使这家总部位于波士顿的公司市值达到12.9亿美元。 Bicara公司在首次公开募股中以每股18美元的价格出售了1750万股股票,筹集了 3.15亿美元,这是其市场发行价范围的上限,此前Bicara公司曾两次增加。近几个月上市的药物开发商Alumis 和Artiva Biotherapeutics 的股价低于其IPO价格。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TPG","BCAX","BK4139","BK4135"],"gpt_icon":0},{"id":"1157360442","title":"异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157360442","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157360442?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:16","pubTimestamp":1726247788,"startTime":"0","endTime":"0","summary":"9月13日,由风险投资巨头TPG支持的生物科技公司Bicara Therapeutics Inc在纳斯达克上市首日,股价大涨45.8%,引发投资者热捧。Bicara Therapeutics是一家专注于开发创新癌症疗法的生物科技公司。在本次IPO中,公司共发行了1320万股股票,融资2.25亿美元,超出了原计划规模。数据显示,今年美国的IPO市场复苏迹象明显,其中以医疗健康板块为重点领域。有分析认为,Bicara Therapeutics超额认购的成功上市预示着资金青睐具有前景的生物科技创新项目,为行业发展带来了新的契机。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"gpt_icon":0},{"id":"2467170624","title":"由 TPG 支持的 Bicara Therapeutics 首次上市即大涨 45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2467170624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467170624?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:14","pubTimestamp":1726247670,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透9月13日 - Bicara Therapeutics 的股价周五首次上市就上涨了45.8%,表明投资者对这家由TPG支持的癌症疗法开发商兴趣浓厚。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPG","BK4139","BCAX","BK4135","LENZ"],"gpt_icon":0},{"id":"2467270506","title":"更新 2-Zenas 生物制药公司首次上市股价上涨近 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2467270506","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467270506?lang=zh_cn&edition=full","pubTime":"2024-09-14 00:58","pubTimestamp":1726246693,"startTime":"0","endTime":"0","summary":" 路透9月13日 - 百时美施贵宝支持的Zenas生物制药公司 周五在纳斯达克首次公开发行股票 ,股价上涨近8%,这是2024年美国首次公开发行股票市场 在经历两年低迷后复苏的一个迹象。投资者对医疗支付公司 Waystar 和临床生物制药公司 CG Oncology 等公司反应热烈,截至上次收盘,这两家公司的交易价格均高于其 IPO 价格。Zenas与Bicara Therapeutics 和生物技术公司MBX Biosciences 同时上市,因为IPO活动在经历了夏季的低迷后有所回升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","LU0267386448.USD","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU1989772923.USD","SLE","LU0061475181.USD","LU0106831901.USD","LU0237698245.USD","BK4559","LU2125154935.USD","LU0882574055.USD","LU1989771016.USD","LU2125154778.USD","LU2242646821.SGD","BK4532","LU1571399168.USD","LU1093756168.USD","LU2357305700.SGD","BCAX","IE00BJT1NW94.SGD","LU1585245621.USD","LU1720051017.SGD","LU0868494617.USD","BK4127","LU0320765646.SGD","LU1261432733.SGD","BK4534","ZBIO","BK4007","LU1989772840.SGD","BK4167","LU1162221912.USD","LU1548497426.USD","BK4585","LU0321505868.SGD","LU0321505439.SGD","CGON","LU1291159041.SGD","BMY","BK4077","LU2360032135.SGD","LU0225771236.USD","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","IPO","LU1074936037.SGD","WAY","LU0098860793.USD"],"gpt_icon":0},{"id":"2467689857","title":"TPG 支持的 Bicara Therapeutics 在美国首次公开募股中融资 3.15 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2467689857","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2467689857?lang=zh_cn&edition=full","pubTime":"2024-09-13 09:22","pubTimestamp":1726190557,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透9月13日 - 由TPG支持的癌症疗法开发商Bicara Therapeutics 周四表示,它在美国的首次公开募股中筹集了3.15亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPG","BK4139","BCAX","BK4135","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bicara.com","stockEarnings":[{"period":"1week","weight":-0.2013},{"period":"1month","weight":-0.2158},{"period":"3month","weight":-0.0128},{"period":"ytd","weight":-0.0128}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bicara Therapeutics Inc.于2018年12月12日在特拉华州注册成立。他们是一家临床阶段的生物制药公司,致力于为实体瘤患者带来变革性的双功能疗法。他们的主要项目阿法是一种双功能抗体,它结合了两个临床验证的靶点,即表皮生长因子受体(EGFR)导向的单克隆抗体和结合人类转化生长因子β(TGF-b)的结构域。通过这种双靶向机制,阿法有可能通过同时阻断癌症细胞固有的EGFR存活和增殖,以及肿瘤微环境(TME)中的免疫抑制性TGF-b信号传导,发挥强大的抗肿瘤活性。Ficerafusp alfa通过与肿瘤细胞上的EGFR结合,将TGF-b抑制剂直接引入TME,他们认为这将导致持久的反应和总生存率或OS的增加,同时减少通常与全身TGF-b抑制相关的不良反应。","exchange":"NASDAQ","name":"Bicara Therapeutics","nameEN":"Bicara Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bicara Therapeutics,BCAX,Bicara Therapeutics股票,Bicara Therapeutics股票老虎,Bicara Therapeutics股票老虎国际,Bicara Therapeutics行情,Bicara Therapeutics股票行情,Bicara Therapeutics股价,Bicara Therapeutics股市,Bicara Therapeutics股票价格,Bicara Therapeutics股票交易,Bicara Therapeutics股票购买,Bicara Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}